阿库提斯生物制药
ARQT
28.82
-0.28
-0.96%
阿库提斯生物制药
US · ARQT
#2465 按市值排名
上市于 2020
28.82
-0.28
-0.96%
实时 - 追踪5344个代码 - 心跳于408秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了2家。
- 机构持股总比例下降了0.1个百分点。
机构持股
- 机构持股比例
- 107.56% -0.15pp
- 机构数量
- 336 +2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund58.37%
Hedge Fund26.52%
VC/PE Fund10.80%
Public Company7.07%
Private Company3.41%
Individual/Insider1.03%
Government Pension Fund0.71%
Sovereign Wealth Fund0.32%
Insurance Company0.31%
主要股东 截至 2026-06-30
Montanova Capital, LLC
9.89% · 12.44M 股
BlackRock
8.39% · 10.55M 股
Frazier Life Sciences Management, LP
7.86% · 9.87M 股
Rubric Capital Management LP
6.58% · 8.27M 股
Polar Capital Holdings Plc
5.26% · 6.61M 股
State Street Global Advisors
4.63% · 5.82M 股
Vanguard Capital Management, LLC
4.62% · 5.80M 股
Morgan Stanley
3.49% · 4.39M 股
Jennison Associates LLC
3.36% · 4.22M 股
D. E. Shaw & Co., L.P.
3.14% · 3.95M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 18次买入 · 31次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Todd Watanabe | Chief Executive Officer | 0.51% |
| Christopher Peetz | Independent Director | 0.15% |
| Patrick Burnett | Senior VP & Chief Medical Officer | 0.09% |
| Latha Vairavan | Vice President of Finance & Investor Relations | 0.07% |
| Larry Edwards | Chief Commercial Officer | 0.05% |
| Patrick Heron | Independent Chairperson | 0.03% |
| Howard Welgus | Director | 0.02% |
| Masaru Matsuda | Senior Vice President | 0.02% |
| Keith Leonard | Independent Director | 0.01% |
| Halley Gilbert | Independent Director | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | Masaru Matsuda | Senior Vice President | Open Market Disposition | -3,674 | $25.00 |
| 2026-09-14 | Howard Welgus | Director | Automatic Disposition | -634 | $24.18 |
| 2026-09-14 | Howard Welgus | Director | Derivative Exercise and Sale | -4,096 | $6.52–24.18 |
| 2026-09-07 | Masaru Matsuda | Senior Vice President | Automatic Disposition | -9,989 | $25.03 |
| 2026-08-26 | Terrie Curran | Independent Director | Derivative Exercise and Sale | -38,200 | $7.51–25.03 |
| 2026-08-19 | Terrie Curran | Independent Director | Derivative Exercise and Sale | -1,072 | $7.51–26.04 |
| 2026-08-18 | Patrick Burnett | Senior VP & Chief Medical Officer | Open Market Disposition | -1,697 | $27.00 |
| 2026-08-16 | Howard Welgus | Director | Automatic Disposition | -634 | $26.18 |
| 2026-08-16 | Howard Welgus | Director | Derivative Exercise and Sale | -4,096 | $6.52–26.18 |
| 2026-08-11 | Patrick Burnett | Senior VP & Chief Medical Officer | Derivative Exercise and Sale | -15,000 | $3.64–26.52 |
| 2026-08-02 | Todd Watanabe | Chief Executive Officer | Open Market Disposition | -4,375 | $26.12 |
| 2026-08-02 | Patrick Burnett | Senior VP & Chief Medical Officer | Open Market Disposition | -955 | $26.12 |
| 2026-08-02 | Masaru Matsuda | Senior Vice President | Open Market Disposition | -1,230 | $26.12 |
| 2026-07-14 | Howard Welgus | Director | Automatic Disposition | -634 | $26.91 |
| 2026-07-14 | Howard Welgus | Director | Derivative Exercise and Sale | -4,096 | $6.52–26.91 |
| 2026-07-14 | Christopher Peetz | Independent Director | Other Acquisition | +4,315 | -- |
| 2026-07-14 | Christopher Peetz | Independent Director | Other Derivative Acquisition | +34,496 | $27.78 |
| 2026-07-14 | Christopher Peetz | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-06-16 | Howard Welgus | Director | Automatic Disposition | -635 | $25.67 |
| 2026-06-14 | Howard Welgus | Director | Derivative Exercise and Sale | -4,096 | $6.52–24.41 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:14 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
阿库提斯生物制药 讨论区 0 条评论